FdaApplication
NDA 022016
Identifiers
- fda_app_no: NDA022016
Properties
| Property | Value |
|---|---|
| applicant_name | CUMBERLAND PHARMS |
| application_type | NDA |
Revenue by product
VAPRISOL
| Period | Revenue |
|---|---|
| Q1 2024 | $0.0M |
| Q3 2023 | $0.0M |
| Q1 2023 | $0.0M |
| Q3 2022 | $-0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VAPRISOL | CONIVAPTAN HYDROCHLORIDE | 20MG | INJECTABLE;INJECTION |
1 product